Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines

Bruna Victorasso Jardim-Perassi, Mateus Repolês Lourenço, Gabriel Mandarini Doho, Ingrid Helen Grígolo, Gabriela Bottaro Gelaleti, Lívia Carvalho Ferreira, Thaiz Ferraz Borin, Marina Gobbe Moschetta, Debora Aparecida Pires de Campos Zuccari

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Angiogenesis is the process of new blood vessel formation, regulated by a number of pro- and antiangiogenic factors and usually begins in response to hypoxia. Exogenous administration of melatonin has shown numerous anti-tumor effects and appears to inhibit tumor angiogenesis. However, many factors involved in the anti-angiogenic effect of melatonin are still under investigation. Here, we evaluate the effects of melatonin on cell viability and expression of angiogenic factors in MCF-7 and MDA-MB-231 breast cancer cells under hypoxic conditions. Cell viability was investigated by MTT and gene and protein expression of the hypoxia-inducible factor-1a (HIF-1α) and vascular endothelial growth factor (VEGF-A) were verified by qPCR and immunocytochemistry after melatonin treatment (1 mM) under hypoxic conditions. Additionally, a protein array with 20 different cytokines/factors was performed on tumor cell lysates. The results showed that 1 mM of melatonin reduced the viability of MCF-7 and MDA-MB-231 cells (p < .05). This treatment also decreased both gene and protein expression of HIF-1a and VEGF-A under hypoxic conditions (p < .05). Among the proteins evaluated by protein array, melatonin treatment during hypoxia reduced VEGF-C, VEGFR receptors (VEGFR2 and VEGFR3), matrix metalloproteinase 9 (MMP9) and Angiogenin in MCF-7 cells. In MDA-MB-231 cells, a significant decrease was observed in VEGFR2, epidermal growth factor receptor (EGFR) and Angiogenin (p < .05). Taken together, these results showed that melatonin acts in the regulation of angiogenic factors in breast tumor cells and suggests an anti-angiogenic activity, particularly under hypoxic conditions.

Original languageEnglish (US)
Pages (from-to)347-348
Number of pages2
JournalAnti-Cancer Agents in Medicinal Chemistry
Volume16
Issue number3
StatePublished - Mar 1 2016
Externally publishedYes

Fingerprint

Angiogenesis Inducing Agents
Melatonin
Breast Neoplasms
Cell Line
Protein Array Analysis
Vascular Endothelial Growth Factor A
Cell Survival
Vascular Endothelial Growth Factor C
Gene Expression
Neoplasms
Proteins
Matrix Metalloproteinase 9
MCF-7 Cells
Hypoxia
Epidermal Growth Factor Receptor
Blood Vessels
Therapeutics
Immunohistochemistry
Cytokines

Keywords

  • Angiogenesis
  • Breast neoplasms
  • Cell hypoxia
  • Cell line
  • Gene expression
  • Melatonin
  • Vascular endothelial growth factors

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Cancer Research

Cite this

Jardim-Perassi, B. V., Lourenço, M. R., Doho, G. M., Grígolo, I. H., Gelaleti, G. B., Ferreira, L. C., ... de Campos Zuccari, D. A. P. (2016). Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anti-Cancer Agents in Medicinal Chemistry, 16(3), 347-348.

Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. / Jardim-Perassi, Bruna Victorasso; Lourenço, Mateus Repolês; Doho, Gabriel Mandarini; Grígolo, Ingrid Helen; Gelaleti, Gabriela Bottaro; Ferreira, Lívia Carvalho; Borin, Thaiz Ferraz; Moschetta, Marina Gobbe; de Campos Zuccari, Debora Aparecida Pires.

In: Anti-Cancer Agents in Medicinal Chemistry, Vol. 16, No. 3, 01.03.2016, p. 347-348.

Research output: Contribution to journalArticle

Jardim-Perassi, BV, Lourenço, MR, Doho, GM, Grígolo, IH, Gelaleti, GB, Ferreira, LC, Borin, TF, Moschetta, MG & de Campos Zuccari, DAP 2016, 'Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines', Anti-Cancer Agents in Medicinal Chemistry, vol. 16, no. 3, pp. 347-348.
Jardim-Perassi BV, Lourenço MR, Doho GM, Grígolo IH, Gelaleti GB, Ferreira LC et al. Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. Anti-Cancer Agents in Medicinal Chemistry. 2016 Mar 1;16(3):347-348.
Jardim-Perassi, Bruna Victorasso ; Lourenço, Mateus Repolês ; Doho, Gabriel Mandarini ; Grígolo, Ingrid Helen ; Gelaleti, Gabriela Bottaro ; Ferreira, Lívia Carvalho ; Borin, Thaiz Ferraz ; Moschetta, Marina Gobbe ; de Campos Zuccari, Debora Aparecida Pires. / Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines. In: Anti-Cancer Agents in Medicinal Chemistry. 2016 ; Vol. 16, No. 3. pp. 347-348.
@article{d90d120d8e4941f7989d80795973f20c,
title = "Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines",
abstract = "Angiogenesis is the process of new blood vessel formation, regulated by a number of pro- and antiangiogenic factors and usually begins in response to hypoxia. Exogenous administration of melatonin has shown numerous anti-tumor effects and appears to inhibit tumor angiogenesis. However, many factors involved in the anti-angiogenic effect of melatonin are still under investigation. Here, we evaluate the effects of melatonin on cell viability and expression of angiogenic factors in MCF-7 and MDA-MB-231 breast cancer cells under hypoxic conditions. Cell viability was investigated by MTT and gene and protein expression of the hypoxia-inducible factor-1a (HIF-1α) and vascular endothelial growth factor (VEGF-A) were verified by qPCR and immunocytochemistry after melatonin treatment (1 mM) under hypoxic conditions. Additionally, a protein array with 20 different cytokines/factors was performed on tumor cell lysates. The results showed that 1 mM of melatonin reduced the viability of MCF-7 and MDA-MB-231 cells (p < .05). This treatment also decreased both gene and protein expression of HIF-1a and VEGF-A under hypoxic conditions (p < .05). Among the proteins evaluated by protein array, melatonin treatment during hypoxia reduced VEGF-C, VEGFR receptors (VEGFR2 and VEGFR3), matrix metalloproteinase 9 (MMP9) and Angiogenin in MCF-7 cells. In MDA-MB-231 cells, a significant decrease was observed in VEGFR2, epidermal growth factor receptor (EGFR) and Angiogenin (p < .05). Taken together, these results showed that melatonin acts in the regulation of angiogenic factors in breast tumor cells and suggests an anti-angiogenic activity, particularly under hypoxic conditions.",
keywords = "Angiogenesis, Breast neoplasms, Cell hypoxia, Cell line, Gene expression, Melatonin, Vascular endothelial growth factors",
author = "Jardim-Perassi, {Bruna Victorasso} and Louren{\cc}o, {Mateus Repol{\^e}s} and Doho, {Gabriel Mandarini} and Gr{\'i}golo, {Ingrid Helen} and Gelaleti, {Gabriela Bottaro} and Ferreira, {L{\'i}via Carvalho} and Borin, {Thaiz Ferraz} and Moschetta, {Marina Gobbe} and {de Campos Zuccari}, {Debora Aparecida Pires}",
year = "2016",
month = "3",
day = "1",
language = "English (US)",
volume = "16",
pages = "347--348",
journal = "Anti-Cancer Agents in Medicinal Chemistry",
issn = "1871-5206",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines

AU - Jardim-Perassi, Bruna Victorasso

AU - Lourenço, Mateus Repolês

AU - Doho, Gabriel Mandarini

AU - Grígolo, Ingrid Helen

AU - Gelaleti, Gabriela Bottaro

AU - Ferreira, Lívia Carvalho

AU - Borin, Thaiz Ferraz

AU - Moschetta, Marina Gobbe

AU - de Campos Zuccari, Debora Aparecida Pires

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Angiogenesis is the process of new blood vessel formation, regulated by a number of pro- and antiangiogenic factors and usually begins in response to hypoxia. Exogenous administration of melatonin has shown numerous anti-tumor effects and appears to inhibit tumor angiogenesis. However, many factors involved in the anti-angiogenic effect of melatonin are still under investigation. Here, we evaluate the effects of melatonin on cell viability and expression of angiogenic factors in MCF-7 and MDA-MB-231 breast cancer cells under hypoxic conditions. Cell viability was investigated by MTT and gene and protein expression of the hypoxia-inducible factor-1a (HIF-1α) and vascular endothelial growth factor (VEGF-A) were verified by qPCR and immunocytochemistry after melatonin treatment (1 mM) under hypoxic conditions. Additionally, a protein array with 20 different cytokines/factors was performed on tumor cell lysates. The results showed that 1 mM of melatonin reduced the viability of MCF-7 and MDA-MB-231 cells (p < .05). This treatment also decreased both gene and protein expression of HIF-1a and VEGF-A under hypoxic conditions (p < .05). Among the proteins evaluated by protein array, melatonin treatment during hypoxia reduced VEGF-C, VEGFR receptors (VEGFR2 and VEGFR3), matrix metalloproteinase 9 (MMP9) and Angiogenin in MCF-7 cells. In MDA-MB-231 cells, a significant decrease was observed in VEGFR2, epidermal growth factor receptor (EGFR) and Angiogenin (p < .05). Taken together, these results showed that melatonin acts in the regulation of angiogenic factors in breast tumor cells and suggests an anti-angiogenic activity, particularly under hypoxic conditions.

AB - Angiogenesis is the process of new blood vessel formation, regulated by a number of pro- and antiangiogenic factors and usually begins in response to hypoxia. Exogenous administration of melatonin has shown numerous anti-tumor effects and appears to inhibit tumor angiogenesis. However, many factors involved in the anti-angiogenic effect of melatonin are still under investigation. Here, we evaluate the effects of melatonin on cell viability and expression of angiogenic factors in MCF-7 and MDA-MB-231 breast cancer cells under hypoxic conditions. Cell viability was investigated by MTT and gene and protein expression of the hypoxia-inducible factor-1a (HIF-1α) and vascular endothelial growth factor (VEGF-A) were verified by qPCR and immunocytochemistry after melatonin treatment (1 mM) under hypoxic conditions. Additionally, a protein array with 20 different cytokines/factors was performed on tumor cell lysates. The results showed that 1 mM of melatonin reduced the viability of MCF-7 and MDA-MB-231 cells (p < .05). This treatment also decreased both gene and protein expression of HIF-1a and VEGF-A under hypoxic conditions (p < .05). Among the proteins evaluated by protein array, melatonin treatment during hypoxia reduced VEGF-C, VEGFR receptors (VEGFR2 and VEGFR3), matrix metalloproteinase 9 (MMP9) and Angiogenin in MCF-7 cells. In MDA-MB-231 cells, a significant decrease was observed in VEGFR2, epidermal growth factor receptor (EGFR) and Angiogenin (p < .05). Taken together, these results showed that melatonin acts in the regulation of angiogenic factors in breast tumor cells and suggests an anti-angiogenic activity, particularly under hypoxic conditions.

KW - Angiogenesis

KW - Breast neoplasms

KW - Cell hypoxia

KW - Cell line

KW - Gene expression

KW - Melatonin

KW - Vascular endothelial growth factors

UR - http://www.scopus.com/inward/record.url?scp=84958986256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958986256&partnerID=8YFLogxK

M3 - Article

C2 - 25963143

AN - SCOPUS:84958986256

VL - 16

SP - 347

EP - 348

JO - Anti-Cancer Agents in Medicinal Chemistry

JF - Anti-Cancer Agents in Medicinal Chemistry

SN - 1871-5206

IS - 3

ER -